Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-17
2006-10-17
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S594000, C548S467000, C514S414000
Reexamination Certificate
active
07122538
ABSTRACT:
The invention provides compounds of formula (I):whereinA and B represent the groups —(CH2)m— and —(CH2)n— respectively;R1represents hydrogen or C1-6alkyl;R2represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pOC3-6cycloalkyl, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, —CO2C1-6alkyl, —CO2NR5R6, —SO2NR5R6, —(CH2)NR5R6, —(CH2)pNR5COR6, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring;R3represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pOC3-6cycloalkyl, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, —CO2C1-6alkyl, —CO2NR7R8, —SO2NR7R8, —(CH2)pNR7R8or —(CH2)pNR7COR8;R4represents hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO2CF3, —(CH2)pC3-6cycloalkyl, —(CH2)qOC1-6alkyl or —(CH2)pOC3-6cycloalkyl;R5and R6each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;R7and R8each independently represent hydrogen or C1-6alkyl;m and n independently represent an integer selected from 1 and 2;p independently represents an integer selected from 0, 1, 2 and 3;q independently represents an integer selected from 1, 2 and 3;or a pharmaceutically acceptable salt or solvate thereof,with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded.The compounds are useful in therapy, in particular as antipsychotic agents.
REFERENCES:
patent: 2005/0222124 (2005-10-01), Bromidge et al.
patent: 10053799 (2002-05-01), None
patent: 0 007 070 (1980-01-01), None
patent: WO0132646 (2001-05-01), None
patent: WO0145694 (2001-06-01), None
patent: WO03068752 (2003-08-01), None
Forbes Ian Thomson
Gribble Andrew Derrick
Lightfoot Andrew P.
Payne Andrew H.
Barker Michael P.
Glaxo Group Limited
Kanagy James M.
Kinzig Charles M.
Saeed Kamal A.
LandOfFree
Sulfonamide derivatives as antipsychotic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamide derivatives as antipsychotic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamide derivatives as antipsychotic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693624